A November 13
th article on the science news site,
ScienceDaily, highlights the findings
of a study suggesting that the hormone estrogen regulates key risk factors
associated with heart disease and stroke. The study is published in the journal
Arteriosclerosis, Thrombosis and Vascular
Biology (
Estrogen's
role in regulating common health disease risks identified).
Scientists from the Schulich School of Medicine &
Dentistry's Robarts Research Institute, in Canada, showed that estrogen can
activate a protein complex called GPER. Once GPER is activated, a protein known
as PCSK-9 is inhibited, which in turn lowers LDL cholesterol. The study also found that women who carry a
variant of the GPER gene have significant increases in LDL cholesterol levels.
This gene variant was found in 20% of the experimental population comprised of
women from northern Alberta and Ontario.
According to Dr. Feldman, one of the study’s authors, these findings
build upon a previous study his team conducted which concluded that GPER activity
could influence blood pressure. He commented that the group’s latest discovery of
the gene’s impact on cholesterol levels increases the importance of determining
whether a woman has altered GPER activity.
Cerilliant provides Certified Spiking Solutions® for a wide
variety of hormones monitored by LC-MS/MS in pregnancy or female health such as
estradiol, progesterone, estriol, estrone, and 17α-ethynylestradiol. These
certified solutions are suitable for MS-based testing methods in current and
emerging critical applications including cancer testing, neonatal screening,
biomarker research, hormone replacement therapy, and clinical chemistry.
Cerilliant reference solutions are produced and certified to the highest industry
standards including ISO 13485, ISO Guide 34, and ISO/IEC 17025 and are
classified as "certified reference materials" in accordance with ISO
requirements. Click on the link below to view Cerilliant Certified Spiking
Solutions® of female hormones: